Lamotrigine

證據等級: L5

預測適應症: 9 個

Note on indication selection: predicted_indications[0] (trigeminal nerve neoplasm) carries score-rank #1 but its own repurposing_rationale flags a label/evidence mismatch (Hold, L5, no MOA relevance) — the cited literature discusses tumor-induced neuralgia symptoms, not neoplasm treatment. predicted_indications[1] (trigeminal neuralgia) has real comparative trial evidence (L2, "Proceed with Guardrails"). I'm featuring trigeminal neuralgia as the report subject since that's the candidate the evidence actually supports — presenting the neoplasm claim as primary would misrepresent the underlying data.

Lamotrigine: From Epilepsy to Trigeminal Neuralgia

One-Sentence Summary

Lamotrigine is a well-established anticonvulsant (sodium-channel blocker) originally developed for epilepsy and later extended to bipolar disorder maintenance treatment. The TxGNN model predicts it may be effective for Trigeminal Neuralgia, with 4 clinical trials (including a direct head-to-head trial against carbamazepine) and 19 publications currently supporting this direction.

Note: TxGNN's single highest-scoring prediction was "trigeminal nerve neoplasm," but the evidence retrieved for that label consists only of tumor-related facial pain and radiosurgery reports with no oncologic relevance — the model has essentially confused the neoplasm label with the neuralgia symptom it can cause. That candidate is scored Hold/L5 and is not carried forward here.

Quick Overview

Item	Content
Original Indication	Epilepsy (anticonvulsant); NZ regulatory filing not available — see Market Status
Predicted New Indication	Trigeminal Neuralgia
TxGNN Prediction Score	99.89%
Evidence Level	L2
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available (data gap DG002). Based on the mechanistic evidence attached to this prediction, lamotrigine acts as a voltage-gated sodium channel blocker that inhibits glutamate release, reducing abnormal neuronal firing in the trigeminal ganglion and brainstem nuclei.

Epilepsy and trigeminal neuralgia share a common pathophysiological substrate: both involve paroxysmal, hyperexcitable neuronal discharge. The first-line drugs for trigeminal neuralgia — carbamazepine and oxcarbazepine — are themselves sodium-channel-blocking anticonvulsants, the same pharmacological class as lamotrigine. This class-level mechanistic overlap is why lamotrigine has been studied as a second-line or add-on agent for trigeminal neuralgia, and why the European Academy of Neurology (EAN) guideline (PMID 30860637) includes it among treatment options when first-line agents fail or are not tolerated.

Two completed trials directly tested lamotrigine against carbamazepine or placebo in trigeminal neuralgia patients (NCT00913107, NCT00203229), lending direct — though small-sample — clinical support to the mechanistic rationale, beyond simple class-effect extrapolation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00913107	Phase 2/3	Completed	21	Direct comparison of lamotrigine efficacy and safety versus carbamazepine in trigeminal neuralgia patients.
NCT00203229	NA	Completed	20	Double-blind, placebo-controlled add-on study of Lamictal (lamotrigine) evaluating efficacy in reducing TN attack frequency and safety.
NCT00243152	NA	Completed	6	fMRI-based exploratory study of lamotrigine's effect on neuropathic facial pain/neuralgia; mechanistic imaging endpoint, not a efficacy trial.
NCT04996199	Phase 4	Unknown	132	Compares carbamazepine vs. oxcarbazepine in TN; does not include lamotrigine arm — included only as same-class indirect reference.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30860637	2019	Guideline	European Journal of Neurology	EAN guideline on trigeminal neuralgia management; anticonvulsants including lamotrigine positioned as options beyond first-line therapy.
37892981	2023	Systematic Review	Biomedicines	Umbrella review of drugs used for TN, evaluating efficacy and side effects across anticonvulsants including lamotrigine.
21621166	2011	Comparative Study	Journal of the Chinese Medical Association	Direct comparative study of lamotrigine vs. carbamazepine efficacy and side-effect profile in TN patients (companion publication to NCT00913107).
30081317	2018	Case Report	Multiple Sclerosis and Related Disorders	Refractory TN in a multiple sclerosis patient successfully controlled with pregabalin plus lamotrigine combination therapy.
34108244	2021	Review	Practical Neurology	Practical diagnostic and management guide for TN, covering pharmacological and surgical options.
31908187	2020	Review	Molecular Pain	Overview of TN pathophysiology through pharmacological treatment, including sodium-channel-targeted agents.
38870050	2024	Review	Expert Review of Neurotherapeutics	Update on TN pharmacotherapy, noting limitations of carbamazepine/oxcarbazepine and discussing alternative anticonvulsants.
39365662	2025	Cohort	Pain	Nationwide Danish disease-trajectory study identifying comorbidities temporally associated with TN (7.2M individuals).
38246671	2024	Review	No Shinkei Geka (Neurological Surgery)	Pharmacological treatment review for TN; notes lamotrigine as an off-label alternative when carbamazepine is not tolerated (Japan).
30178160	2018	Review	Drugs	Review of current and innovative pharmacological options for typical and atypical TN.

New Zealand Market Information

Lamotrigine currently has no marketed products or authorizations recorded in New Zealand (market_status: 未上市, 0 licenses on file). Regulatory filing and package-insert data would need to be sourced from Medsafe directly before any local development pathway can be assessed.

Safety Considerations

Please refer to the package insert for safety information — no structured warnings, contraindications, or drug-interaction data were returned for this candidate (DG001, Blocking: TFDA/Medsafe package insert not yet obtained).

One relevant safety signal did surface independently in the literature search performed for a related seizure-indication candidate: a 2025 target-trial study, 40499085 (Neurology), examined a possible association between lamotrigine and ventricular arrhythmias versus levetiracetam. This is not part of the structured safety dataset but should be incorporated once formal safety data collection (DG001) is completed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed trials directly comparing lamotrigine to carbamazepine/placebo in trigeminal neuralgia, reinforced by an EAN guideline listing it as a treatment option and a matching class-mechanism rationale, support proceeding — but sample sizes (n=20–21) are too small to be conclusive, and no New Zealand regulatory or safety-label data currently exist for this drug.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications, DDI) — currently blocking (DG001)
Confirmed DrugBank mechanism-of-action record (DG002)
A larger, adequately powered confirmatory RCT in trigeminal neuralgia
Assessment of the recent lamotrigine–cardiac arrhythmia signal (PMID 40499085) before advancing to clinical use
Clarification of New Zealand market/registration pathway given current "not marketed" status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.